Apyx Medical
APYX
62 hedge funds and large institutions have $99.4M invested in Apyx Medical in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 11 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
31% more capital inflows, than outflows
Capital inflows: $5.77M | Capital outflows: $4.39M
0.56% more ownership
Funds ownership: 51.8% → 52.36% (+0.56%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less funds holding
Funds holding: 67 → 62 (-5)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.23M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$599K |
| 3 |
PVI
Pura Vida Investments
New York
|
+$510K |
| 4 |
Goldman Sachs
New York
|
+$447K |
| 5 |
Cowen and Company
New York
|
+$409K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Silvercrest Asset Management
New York
|
-$1.24M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$699K |
| 3 |
Raymond James & Associates
St Petersburg,
Florida
|
-$613K |
| 4 |
ACM
Archon Capital Management
Seattle,
Washington
|
-$465K |
| 5 |
Renaissance Technologies
New York
|
-$230K |
APYX Hedge Fund Activity: Q2 2020 in Review
62 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Apyx Medical (APYX) for Q2 2020, worth a combined $99.4M — up 56% from $63.5M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of APYX and 7 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 27 added.
The largest buyer was JP Morgan Chase, adding an estimated $2.23M. The largest seller was Silvercrest Asset Management, exiting entirely with an estimated $1.24M sold.
- 62 institutional investors held Apyx Medical (APYX) as of Q2 2020, down from 67 in Q1 2020.
- Funds reported $99.4M of Apyx Medical stock for Q2 2020, up 56% quarter-over-quarter.
- 7 funds opened new Apyx Medical positions in Q2 2020 and 11 closed out, a net change of -4 holders.
- The largest Apyx Medical buyer in Q2 2020 was JP Morgan Chase, an estimated $2.23M added.
- The largest Apyx Medical seller in Q2 2020 was Silvercrest Asset Management, an estimated $1.24M sold.
Based on aggregated 13F filings for Q2 2020.